Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer’s disease
Cell reports. Medicine, 2026;:102906
A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice
Diabetes, obesity & metabolism, 2026
Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets
Pharmaceutics, 2026;18(7)
Lead-guided prodrug development of small molecules as GLP-1R agonists
Bioorganic chemistry, 2026;180:110210
PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction
Nature communications, 2026;17(1)
Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice
Diabetes, 2026
Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Male Diabetic Rats
Behavioural brain research, 2026;:116343
Discovery of DDO-4279 as a PP5 degrader for the treatment of obesity
RSC medicinal chemistry, 2026
Differential Anti-Inflammatory Effects of Semaglutide and Tirzepatide in Experimental Diabetes Mellitus
Current issues in molecular biology, 2026;48(7)
A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026;201:119717
GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications
Ophthalmology and therapy, 2026
Chronic semaglutide alters ingestive behavior without impairing taste function in mice
Molecular metabolism, 2026;:102410
From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling
Cardiovascular diabetology. Endocrinology reports, 2026;12(1)
Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2026;:115167
Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE-/- mice
Pharmacological research, 2026;:108321
Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study
Pharmaceutics, 2026;18(7)
Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition
Journal of orthopaedic translation, 2026;59:101166
GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies
Biological psychiatry, 2026
LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis
International journal of obesity (2005), 2026
Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome
Frontiers in immunology, 2026;17:1849387